The market map is not the strategy
A large population, a growing disease burden or an expanding budget can establish relevance. None establishes an attractive business. I start with the transaction that turns need into funded care, then ask which participant can change its terms. That participant may be a payer, a hospital, an employer, a pharmacy network, a clinical group or a distribution partner.
The strategic task is to improve the organization’s position in that system. This may require a better care pathway, a distinctive delivery capability, credible evidence, or a less concentrated route to market. More scale helps only if it changes the economics of serving people or the alternatives available in a negotiation.
Read payer mix as structural exposure
The strategic implication is concentration of economic exposure: the number of patients and the distribution of revenue can tell very different stories. It does not follow that clinical decisions should favor a payer class. It follows that management needs a credible resilience plan for rate changes, contract renewal and the cost of maintaining access.
I would map revenue, contribution, cash timing and service obligations by counterparty, then examine the consequences of losing one channel or repricing one contract. The most useful scenario may be a flat-volume year with worse terms, not an optimistic demand forecast.
Build a better outside option
A negotiating position improves when the organization can serve its mission through another viable route. That can mean a second referral corridor, a different purchaser, a partner with complementary reach, or a capability that buyers cannot easily replace. Each alternative has a cost; a nominal option with no delivery capacity is not an outside option.
This is where commercial strategy meets operating design. Reliable access, lower implementation burden and demonstrable service quality can make a proposition more valuable to the counterparty. An exclusive contract may offer distribution today while limiting customer access, data use or renewal rights tomorrow. I would price those restrictions as part of the deal.
Choose the boundary of the enterprise
| Choice | What it can secure | What must be underwritten |
|---|---|---|
| Own | Direct control of a scarce capability and its operating priorities. | Capital intensity, integration capacity, fixed cost and the consequences of concentrated exposure. |
| Partner | Access to complementary capability without reproducing the entire infrastructure. | Service obligations, economic share, information rights, renewal and termination. |
| Contract | A defined service or capacity commitment with a narrower operating perimeter. | Enforceability, availability under stress, pricing resets and substitutability. |
| Defer | Preserve resources while uncertainty is resolved. | The cost of waiting, expiry of the opportunity and what evidence will change the decision. |
Ownership is justified when the missing decision rights matter enough to compensate for the capital and execution burden. Partnership is justified when shared incentives can deliver the outcome reliably. These are alternatives to compare against the same capability requirement, not expressions of ambition.
Distribution has to earn retention
My test for distribution advantage is whether the relationship improves the customer’s recurring work. Shared infrastructure should reduce repeated effort, improve access or strengthen service delivery. Cross-selling without that improvement is an extraction strategy vulnerable to a better alternative.
The counterweight is autonomy. A useful ecosystem preserves clinical judgment, patient choice and a practical route to information portability. Retention produced by value is strategically different from retention produced by friction.
The leadership decision
I would ask the executive team to identify its three most consequential dependencies, the event that could change each relationship, and the investment that would improve its alternatives. Then I would compare that investment with spending the same resources on additional volume.
The recommendation should specify what the business must control, where it can cooperate, what it will deliberately leave outside its perimeter and how the chosen boundary affects patients, clinicians and counterparties. That is a strategy the board can debate and management can execute.
Sources & analytical basis
The strategic recommendations are the author’s interpretation. External research and company observations are attributed below; illustrative scenarios are labeled where used.